- A. CD56
- B. CD20 ✓
- C. CD4
- D. CD8
Rituximab targets CD20, which is a specific B-cell surface antigen. In other words, Rituximab targets the CD20 antigen. CD20 is a cell surface protein that is primarily expressed on B cells, making it an ideal target for rituximab in the treatment of B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.
